Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Vofatamab
Synonyms
Therapy Description	Vofatamab (B-701) is a monoclonal antibody, which binds FGFR3 to prevent phosphorylation and signaling, thereby inhibiting proliferation and promoting apoptosis in cancer cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534, PMID: 22203368).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Vofatamab		B-701\|MFGR1877S\|RG-7444\|R3Mab	FGFR3 Antibody 5	Vofatamab (B-701) is a monoclonal antibody, which binds FGFR3 to prevent phosphorylation and signaling, thereby inhibiting proliferation and promoting apoptosis in cancer cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534, PMID: 22203368).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 8 of 8 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR3 over exp	multiple myeloma	sensitive	Vofatamab	Phase I	Actionable	In a Phase I trial, Vofatamab (B-701) demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).	detail...
FGFR3 S249C	bladder carcinoma	sensitive	Vofatamab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Vofatamab (B-701) decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019).	19381019
FGFR3 wild-type	bladder carcinoma	sensitive	Vofatamab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Vofatamab (B-701) decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).	19381019
FGFR3 G372C	Advanced Solid Tumor	sensitive	Vofatamab	Preclinical - Cell culture	Actionable	In a preclinical study, Vofatamab (B-701) inhibited ligand-dependent proliferation in cells expressing FGFR3 G372C (PMID: 19381019).	19381019
FGFR3 K652E	Advanced Solid Tumor	sensitive	Vofatamab	Preclinical - Cell culture	Actionable	In a preclinical study, Vofatamab (B-701) inhibited ligand-dependent cell proliferation in cells expressing FGFR3 K652E in culture (PMID: 19381019).	19381019
FGFR3 R248C	Advanced Solid Tumor	sensitive	Vofatamab	Preclinical - Cell culture	Actionable	In a preclinical study, Vofatamab (B-701) inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).	19381019
FGFR3 S249C	Advanced Solid Tumor	sensitive	Vofatamab	Preclinical - Cell culture	Actionable	In a preclinical study, Vofatamab (B-701) inhibited proliferation of transformed cells expressing FGFR3 S249C in culture (PMID: 19381019).	19381019
FGFR3 Y375C	Advanced Solid Tumor	sensitive	Vofatamab	Preclinical - Cell culture	Actionable	In a preclinical study, Vofatamab (B-701) inhibited ligand-dependent proliferation of cells expressing FGFR3 Y375C in culture (PMID: 19381019).	19381019

Showing 1 to 8 of 8 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02401542	Phase Ib/II	Docetaxel + Vofatamab Vofatamab Docetaxel	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)	Terminated	USA \| TUR \| SWE \| ITA \| GBR \| ESP \| CZE	2

Showing 1 to 1 of 1 entries

Filter rows:

Additional content available in CKB BOOST